HKG:2607 Revenue

In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B CNY with 5.75% growth. Shanghai Pharmaceuticals Holding had revenue of 65.62B in the quarter ending December 31, 2024, with 4.52% growth.

Revenue

275.25B CNY

Revenue Growth

+5.75%

P/S Ratio

0.22

Revenue / Employee

5.57M CNY

Employees

49,402

Market Cap

64.27B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
BeiGene	29.60B
Hansoh Pharmaceutical Group Company	13.05B
JD Health International	61.89B
WuXi Biologics	19.87B
Innovent Biologics	10.03B
Akeso	2.26B
Alibaba Health Information Technology	31.39B
Sino Biopharmaceutical	30.72B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

4 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
4 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News